ES3004083T3 - Mass spectrometry assay method for detection and quantitation of kidney function metabolites - Google Patents
Mass spectrometry assay method for detection and quantitation of kidney function metabolites Download PDFInfo
- Publication number
- ES3004083T3 ES3004083T3 ES17885159T ES17885159T ES3004083T3 ES 3004083 T3 ES3004083 T3 ES 3004083T3 ES 17885159 T ES17885159 T ES 17885159T ES 17885159 T ES17885159 T ES 17885159T ES 3004083 T3 ES3004083 T3 ES 3004083T3
- Authority
- ES
- Spain
- Prior art keywords
- analytes
- ion
- analyte
- tryptophan
- mobile phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004949 mass spectrometry Methods 0.000 title claims abstract description 53
- 230000003907 kidney function Effects 0.000 title description 10
- 238000003556 assay Methods 0.000 title description 6
- 238000001514 detection method Methods 0.000 title description 5
- 239000002207 metabolite Substances 0.000 title description 5
- 150000002500 ions Chemical class 0.000 claims abstract description 196
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 173
- 238000000034 method Methods 0.000 claims abstract description 119
- 229940109239 creatinine Drugs 0.000 claims abstract description 87
- PEDXUVCGOLSNLQ-WUJLRWPWSA-N N-acetyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(C)=O PEDXUVCGOLSNLQ-WUJLRWPWSA-N 0.000 claims abstract description 81
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 75
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims abstract description 74
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims abstract description 73
- 229930185560 Pseudouridine Natural products 0.000 claims abstract description 73
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims abstract description 73
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims abstract description 73
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 72
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 40
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims abstract description 37
- 229960000367 inositol Drugs 0.000 claims abstract description 37
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims abstract description 37
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 37
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 36
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 35
- 102100028630 Cytoskeleton-associated protein 2 Human genes 0.000 claims abstract description 33
- 101000766848 Homo sapiens Cytoskeleton-associated protein 2 Proteins 0.000 claims abstract description 33
- WOERBKLLTSWFBY-UHFFFAOYSA-M dihydrogen phosphate;tetramethylazanium Chemical compound C[N+](C)(C)C.OP(O)([O-])=O WOERBKLLTSWFBY-UHFFFAOYSA-M 0.000 claims abstract description 32
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 claims abstract description 32
- -1 C-glycosyltryptophan Chemical compound 0.000 claims abstract description 29
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims abstract description 28
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 28
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims abstract description 27
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 27
- 239000004202 carbamide Substances 0.000 claims abstract description 21
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 claims abstract description 19
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 claims abstract description 19
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 19
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims abstract description 19
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 claims abstract description 18
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 18
- 239000012491 analyte Substances 0.000 claims description 116
- 229960004799 tryptophan Drugs 0.000 claims description 75
- 238000011002 quantification Methods 0.000 claims description 71
- 238000002347 injection Methods 0.000 claims description 45
- 239000007924 injection Substances 0.000 claims description 45
- 238000004811 liquid chromatography Methods 0.000 claims description 21
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 5
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 claims description 2
- KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-WCMJATGVSA-N (2R,4R)-(1,2,3,4,5-13C5)pentane-1,2,3,4,5-pentol Chemical compound [13CH2]([13C@@H](O)[13C@H](O)[13C@H](O)[13CH2]O)O HEBKCHPVOIAQTA-WCMJATGVSA-N 0.000 claims 1
- JDHILDINMRGULE-FYFSCIFKSA-N (2S)-2-amino-3-[3-(trideuteriomethyl)imidazol-4-yl]propanoic acid Chemical compound C(N1C=NC=C1C[C@H](N)C(=O)O)([2H])([2H])[2H] JDHILDINMRGULE-FYFSCIFKSA-N 0.000 claims 1
- QJYMWMDDBANNAM-QXYVSOOMSA-N (2S)-2-deuterio-2-(dideuterioamino)-3-hydroxy-4-oxopentanoic acid Chemical compound C(C)(=O)C([C@](N([2H])[2H])(C(=O)O)[2H])O QJYMWMDDBANNAM-QXYVSOOMSA-N 0.000 claims 1
- DDRJAANPRJIHGJ-FIBGUPNXSA-N 2-Amino-3-(trideuteriomethyl)-4H-imidazol-5-one Chemical compound [2H]C([2H])([2H])N1CC(=O)N=C1N DDRJAANPRJIHGJ-FIBGUPNXSA-N 0.000 claims 1
- PEDXUVCGOLSNLQ-LUAMTSQFSA-N 2-deuterio-2-[deuterio-(2,2,2-trideuterioacetyl)amino]-3-hydroxybutanoic acid Chemical compound C(C([2H])([2H])[2H])(=O)N(C(C(O)C)(C(=O)O)[2H])[2H] PEDXUVCGOLSNLQ-LUAMTSQFSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- XSQUKJJJFZCRTK-OUBTZVSYSA-N Urea-13C Chemical compound N[13C](N)=O XSQUKJJJFZCRTK-OUBTZVSYSA-N 0.000 claims 1
- 229960002898 threonine Drugs 0.000 claims 1
- 239000012071 phase Substances 0.000 description 147
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 87
- 239000000523 sample Substances 0.000 description 85
- 238000004587 chromatography analysis Methods 0.000 description 64
- 210000002966 serum Anatomy 0.000 description 64
- 210000002381 plasma Anatomy 0.000 description 61
- 238000003908 quality control method Methods 0.000 description 53
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 48
- 238000004885 tandem mass spectrometry Methods 0.000 description 36
- 238000000926 separation method Methods 0.000 description 35
- 239000007789 gas Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 238000011084 recovery Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 24
- 235000019253 formic acid Nutrition 0.000 description 24
- 230000014759 maintenance of location Effects 0.000 description 22
- 238000013467 fragmentation Methods 0.000 description 21
- 238000006062 fragmentation reaction Methods 0.000 description 21
- 238000002552 multiple reaction monitoring Methods 0.000 description 20
- 238000010828 elution Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 238000011067 equilibration Methods 0.000 description 14
- 239000000470 constituent Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 10
- 238000001360 collision-induced dissociation Methods 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- 239000000908 ammonium hydroxide Substances 0.000 description 8
- 238000004807 desolvation Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000006199 nebulizer Substances 0.000 description 8
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000005695 Ammonium acetate Substances 0.000 description 7
- 229940043376 ammonium acetate Drugs 0.000 description 7
- 235000019257 ammonium acetate Nutrition 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 238000000132 electrospray ionisation Methods 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013375 chromatographic separation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CPXSBHKDEPPWIX-MKWJWUHGSA-N (2S)-2-amino-3-[2-[(3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-1H-indol-3-yl]propanoic acid Chemical compound C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)C1=C(C[C@H](N)C(=O)O)C2=CC=CC=C2N1 CPXSBHKDEPPWIX-MKWJWUHGSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QIVBCDIJIAJPQS-XDACSXLQSA-N (2s)-2-(deuterioamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](N[2H])C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-XDACSXLQSA-N 0.000 description 2
- CPXSBHKDEPPWIX-RAYCSJGISA-N 2'-alpha-mannosyl-L-tryptophan Chemical compound N1C2=CC=CC=C2C(C[C@H](N)C(O)=O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O CPXSBHKDEPPWIX-RAYCSJGISA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000012192 Cystatin C Human genes 0.000 description 2
- 108010061642 Cystatin C Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JJIHLJJYMXLCOY-UHFFFAOYSA-N N-Acetyl-DL-serine Chemical compound CC(=O)NC(CO)C(O)=O JJIHLJJYMXLCOY-UHFFFAOYSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000012482 calibration solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000002553 single reaction monitoring Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004544 sputter deposition Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- KAXRWMOLNJZCEW-QRPNPIFTSA-N (2s)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N KAXRWMOLNJZCEW-QRPNPIFTSA-N 0.000 description 1
- PMMYEEVYMWASQN-QAFFOARNSA-N (2s,4r)-2,5,5-trideuterio-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound [2H]C1([2H])N[C@]([2H])(C(O)=O)C[C@H]1O PMMYEEVYMWASQN-QAFFOARNSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- JFLIEFSWGNOPJJ-YEYTVMCYSA-N C1(=CC=CC=C1)CC(=O)N[C@@H](CCC(N)=O)C(=O)O[2H] Chemical compound C1(=CC=CC=C1)CC(=O)N[C@@H](CCC(N)=O)C(=O)O[2H] JFLIEFSWGNOPJJ-YEYTVMCYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 229940029378 iothalamate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000012627 multivariate algorithm Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0009—Calibration of the apparatus
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
- H01J49/0031—Step by step routines describing the use of the apparatus
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
- H01J49/0045—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn characterised by the fragmentation or other specific reaction
- H01J49/005—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn characterised by the fragmentation or other specific reaction by collision with gas, e.g. by introducing gas or by accelerating ions with an electric field
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/14—Ion sources; Ion guns using particle bombardment, e.g. ionisation chambers
- H01J49/145—Ion sources; Ion guns using particle bombardment, e.g. ionisation chambers using chemical ionisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435967P | 2016-12-19 | 2016-12-19 | |
| US201762526043P | 2017-06-28 | 2017-06-28 | |
| US201762558014P | 2017-09-13 | 2017-09-13 | |
| PCT/US2017/066364 WO2018118630A1 (en) | 2016-12-19 | 2017-12-14 | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3004083T3 true ES3004083T3 (en) | 2025-03-11 |
Family
ID=62627087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17885159T Active ES3004083T3 (en) | 2016-12-19 | 2017-12-14 | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11619636B2 (enExample) |
| EP (1) | EP3555615B9 (enExample) |
| JP (1) | JP7393206B2 (enExample) |
| CN (1) | CN110088615B (enExample) |
| AU (1) | AU2017382744B2 (enExample) |
| CA (1) | CA3045022C (enExample) |
| ES (1) | ES3004083T3 (enExample) |
| WO (1) | WO2018118630A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3555615B9 (en) | 2016-12-19 | 2025-03-19 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
| CA3110864A1 (en) * | 2018-09-11 | 2020-03-19 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of microbiota-related metabolites |
| US20220189751A1 (en) * | 2019-04-24 | 2022-06-16 | Shimadzu Corporation | Imaging mass spectrometer |
| CN113892029A (zh) * | 2019-05-31 | 2022-01-04 | 梅塔博隆股份有限公司 | 用于检测代谢物的质谱分析方法 |
| CN112946150B (zh) * | 2019-11-26 | 2024-06-18 | 深圳华大临床检验中心 | 一种快速检测人体尿液中高香草酸、香草扁桃酸、5-羟基吲哚乙酸及肌酐的方法及试剂盒 |
| CN111007173A (zh) * | 2019-12-20 | 2020-04-14 | 辉源生物科技（上海）有限公司 | 吲哚胺2，3-二氧化酶抑制剂的筛选方法 |
| WO2021232211A1 (zh) * | 2020-05-19 | 2021-11-25 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| CN115917323A (zh) * | 2020-05-19 | 2023-04-04 | 赛诺菲 | 使用干血样验证药物水平的方法 |
| CN114518413B (zh) * | 2020-11-18 | 2024-12-31 | 江苏天士力帝益药业有限公司 | 一种卡托普利原料药中脯氨酸的含量测定方法 |
| CN114216984B (zh) * | 2021-12-16 | 2023-10-13 | 川北医学院附属医院 | 一种骨质疏松症负离子诊断标志物及其检测方法 |
| CN114414700A (zh) * | 2022-01-27 | 2022-04-29 | 重庆迪纳利医药科技有限责任公司 | 一种同时测定生物样品中多种内源性糖醇含量的方法和系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090194685A1 (en) | 2008-01-31 | 2009-08-06 | Mds Analytical Technologies | High-throughput screening of metabolic disorders using a laser desorption ion source coupled to a mass analyzer |
| JP5624709B2 (ja) * | 2008-03-13 | 2014-11-12 | 大日本住友製薬株式会社 | 内因性代謝物の分析方法 |
| JP5197846B2 (ja) * | 2009-04-30 | 2013-05-15 | 紀陽 田仲 | 腎疾患重篤度を判定する方法又は装置若しくはその作動方法 |
| EP3511973B1 (en) * | 2010-12-28 | 2021-08-04 | Quest Diagnostics Investments LLC | Quantitation of insulin by mass spectrometry |
| EP2788763A4 (en) * | 2011-12-09 | 2015-10-07 | Metabolon Inc | BIOMARKERS FOR RENAL CANCER AND METHODS OF USE |
| CN102680599A (zh) * | 2012-05-11 | 2012-09-19 | 上海特敏生物医药科技有限公司 | 尿肌氨酸及肌酐测定试剂盒 |
| WO2014120449A1 (en) * | 2013-01-31 | 2014-08-07 | Metabolon, Inc. | Biomarkers related to insulin resistance progression and methods using the same |
| MX391220B (es) * | 2013-05-14 | 2025-03-21 | Metabolon Inc | Biomarcadores relacionados a la funcion renal y metodos para usar los mismos. |
| CN105143872B (zh) * | 2013-06-07 | 2019-03-01 | 皮尔斯生物科技有限公司 | 通过质谱分析用复用内标物对蛋白质和蛋白质修饰的绝对定量 |
| ES2731678T3 (es) * | 2013-07-31 | 2019-11-18 | Pharnext | Herramientas de diagnóstico para la enfermedad de Alzheimer |
| US20170276669A1 (en) * | 2014-08-15 | 2017-09-28 | The Johns Hopkins University | Precise estimation of glomerular filtration rate from multiple biomarkers |
| CN105738626B (zh) * | 2014-12-12 | 2017-07-14 | 中国科学院大连化学物理研究所 | 一种新的血清代谢物的组合及其作为肝癌诊断标志物的用途 |
| EP3278100B1 (en) * | 2015-03-28 | 2023-06-14 | Tecan SP, Inc. | Methods and uses comprising solid phase extraction, derivatization with crown ethers, and mass spectrometry |
| CN107850568A (zh) * | 2015-05-27 | 2018-03-27 | 奎斯特诊断投资有限公司 | 用于质谱定量由微量取样装置提取的分析物的方法 |
| CN104897821A (zh) * | 2015-06-03 | 2015-09-09 | 福建中烟工业有限责任公司 | 提取样品中肌醇的方法、试剂盒及其用途 |
| EP3555615B9 (en) | 2016-12-19 | 2025-03-19 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
-
2017
- 2017-12-14 EP EP17885159.8A patent/EP3555615B9/en active Active
- 2017-12-14 US US16/466,451 patent/US11619636B2/en active Active
- 2017-12-14 CN CN201780078615.8A patent/CN110088615B/zh active Active
- 2017-12-14 JP JP2019553158A patent/JP7393206B2/ja active Active
- 2017-12-14 AU AU2017382744A patent/AU2017382744B2/en active Active
- 2017-12-14 ES ES17885159T patent/ES3004083T3/es active Active
- 2017-12-14 CA CA3045022A patent/CA3045022C/en active Active
- 2017-12-14 WO PCT/US2017/066364 patent/WO2018118630A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN110088615B (zh) | 2023-08-22 |
| JP2020502544A (ja) | 2020-01-23 |
| EP3555615B9 (en) | 2025-03-19 |
| JP7393206B2 (ja) | 2023-12-06 |
| EP3555615A1 (en) | 2019-10-23 |
| AU2017382744B2 (en) | 2023-02-09 |
| CA3045022C (en) | 2024-01-16 |
| CA3045022A1 (en) | 2018-06-28 |
| WO2018118630A1 (en) | 2018-06-28 |
| CN110088615A (zh) | 2019-08-02 |
| EP3555615A4 (en) | 2020-11-04 |
| EP3555615B1 (en) | 2024-10-30 |
| US20190346455A1 (en) | 2019-11-14 |
| AU2017382744A1 (en) | 2019-06-13 |
| US11619636B2 (en) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3004083T3 (en) | Mass spectrometry assay method for detection and quantitation of kidney function metabolites | |
| Nalbantoglu | Metabolomics: basic principles and strategies | |
| US11181530B2 (en) | Mass spectrometry method for detection and quantitation of metabolites | |
| Ren et al. | Advances in mass spectrometry-based metabolomics for investigation of metabolites | |
| Wong et al. | An overview of label-free quantitation methods in proteomics by mass spectrometry | |
| US11061005B2 (en) | Mass spectrometry assay method for detection and quantitation of organic acid metabolites | |
| US9063119B2 (en) | Methods for detecting vitamin C by mass spectrometry | |
| US11536726B2 (en) | Mass spectrometry assay method for detection and quantitation of liver function metabolites | |
| Peters et al. | Generic sample preparation combined with high-resolution liquid chromatography–time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories | |
| BR112014012366B1 (pt) | processo para a determinação da quantidade de triiodotironina inversa por espectrometria de massa | |
| Chekmeneva et al. | Development of nanoelectrospray high resolution isotope dilution mass spectrometry for targeted quantitative analysis of urinary metabolites: application to population profiling and clinical studies | |
| CN106370741A (zh) | 一种基于亲水作用色谱飞行时间质谱的喉癌血清差异代谢物的测定筛选方法 | |
| HK40014572A (en) | Mass spectrometry assay method for detection and quantitation of kidney function metabolites | |
| HK40014572B (en) | Mass spectrometry assay method for detection and quantitation of kidney function metabolites | |
| US20250172548A1 (en) | Methods and systems for using isotopically labeled analytes for calibration for quantification of analytes in dried samples | |
| Sommer et al. | Standardized targeted metabolomics using the BIOCRATES MxP quant 500 Kit on the ACQUITY UPLC I-class PLUS and Xevo TQ-XS mass spectrometer | |
| Zheng et al. | A rapid and sensitive LC–MS–MS method for determination of hepcidin-25 in human serum, and measurement of its diurnal rhythm for healthy subjects | |
| Zhang et al. | Introduction to Mass Spectrometry for Bimolecular Analysis in a Clinical Laboratory | |
| Liang et al. | High-throughput metabolic profiling, combined with chemometrics and bioinformatic analysis reveals functional alterations in myocardial dysfunction | |
| AU2024247888A1 (en) | Methods for quantitation of adiponectin by mass spectrometry | |
| PAPAGIANNOPOULOU | Metabolomics’ study for the predisposing factors of cardiotoxicity occurrence, in pediatric patients with neoplasia submitted to different antineoplastic protocols. | |
| Gika et al. | Application of UHPLC-MS to Metabolomic/metabonomic Studies in Man |